CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial

Yuankai Shi1,†, Jin Li2†, Jianming Xu3†, Yan Sun1, Liwei Wang4, Ying Cheng5, Wei Liu6, Guoping Sun7, Yigui Chen8, Li Bai9, Yiping Zhang10, Xiaohui He1, Yi Luo11, Zhehai Wang12, Yunpeng Liu13, Qiang Yao14, Yuhong Li15, Shukui Qin16, Xiaohua Hu17, Feng Bi18, Rongsheng Zheng19 and Xuenong Ouyang20

Abstract

Background: The 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX) regimen is the standard first-line treatment for metastatic colorectal cancer (mCRC), however, the optimal second-line regimen for KRAS wild-type mCRC patients is still investigational. In this study, we aimed to determine the clinical efficacy and safety of CMAB009 plus irinotecan compared to irinotecan-only as a second-line regimen for treating KRAS wild-type mCRC patients.

Methods: Patients with KRAS wild-type mCRC who had previously failed to respond to FOLFOX treatment were randomly assigned in a 2:1 ratio, to receive CMAB009 plus irinotecan or irinotecan-only. Patients receiving irinotecan-only were permitted to switch to CMAB009 therapy on disease progression and were grouped as the sequential-CMAB009 arm. The primary endpoints were overall response rate (ORR) and median progression-free survival (PFS). The secondary endpoints were median overall survival (OS), disease control rate (DCR), clinical benefit rate (CBR), and duration of response (DOR).

Results: The CMAB009 plus irinotecan arm demonstrated significantly improved ORR (33.2% vs. 12.8%; \( P < 0.001 \)) and longer median PFS (169 days vs. 95 days; \( P < 0.001 \)) as compared to the irinotecan-only arm. Patients receiving irinotecan-only were permitted to switch to CMAB009 therapy on disease progression and were grouped as the sequential-CMAB009 arm. The primary endpoints were overall response rate (ORR) and median progression-free survival (PFS). The secondary endpoints were median overall survival (OS), disease control rate (DCR), clinical benefit rate (CBR), and duration of response (DOR).

Results: The CMAB009 plus irinotecan arm demonstrated significantly improved ORR (33.2% vs. 12.8%; \( P < 0.001 \)) and longer median PFS (169 days vs. 95 days; \( P < 0.001 \)) as compared to the irinotecan-only arm. Patients receiving irinotecan-only were permitted to switch to CMAB009 therapy on disease progression and were grouped as the sequential-CMAB009 arm. The primary endpoints were overall response rate (ORR) and median progression-free survival (PFS). The secondary endpoints were median overall survival (OS), disease control rate (DCR), clinical benefit rate (CBR), and duration of response (DOR).

Results: The CMAB009 plus irinotecan arm demonstrated significantly improved ORR (33.2% vs. 12.8%; \( P < 0.001 \)) and longer median PFS (169 days vs. 95 days; \( P < 0.001 \)) as compared to the irinotecan-only arm. Patients receiving irinotecan-only were permitted to switch to CMAB009 therapy on disease progression and were grouped as the sequential-CMAB009 arm. The primary endpoints were overall response rate (ORR) and median progression-free survival (PFS). The secondary endpoints were median overall survival (OS), disease control rate (DCR), clinical benefit rate (CBR), and duration of response (DOR).

Results: The CMAB009 plus irinotecan arm demonstrated significantly improved ORR (33.2% vs. 12.8%; \( P < 0.001 \)) and longer median PFS (169 days vs. 95 days; \( P < 0.001 \)) as compared to the irinotecan-only arm. Patients receiving irinotecan-only were permitted to switch to CMAB009 therapy on disease progression and were grouped as the sequential-CMAB009 arm. The primary endpoints were overall response rate (ORR) and median progression-free survival (PFS). The secondary endpoints were median overall survival (OS), disease control rate (DCR), clinical benefit rate (CBR), and duration of response (DOR).

Results: The CMAB009 plus irinotecan arm demonstrated significantly improved ORR (33.2% vs. 12.8%; \( P < 0.001 \)) and longer median PFS (169 days vs. 95 days; \( P < 0.001 \)) as compared to the irinotecan-only arm. Patients receiving irinotecan-only were permitted to switch to CMAB009 therapy on disease progression and were grouped as the sequential-CMAB009 arm. The primary endpoints were overall response rate (ORR) and median progression-free survival (PFS). The secondary endpoints were median overall survival (OS), disease control rate (DCR), clinical benefit rate (CBR), and duration of response (DOR).

Results: The CMAB009 plus irinotecan arm demonstrated significantly improved ORR (33.2% vs. 12.8%; \( P < 0.001 \)) and longer median PFS (169 days vs. 95 days; \( P < 0.001 \)) as compared to the irinotecan-only arm. Patients receiving irinotecan-only were permitted to switch to CMAB009 therapy on disease progression and were grouped as the sequential-CMAB009 arm. The primary endpoints were overall response rate (ORR) and median progression-free survival (PFS). The secondary endpoints were median overall survival (OS), disease control rate (DCR), clinical benefit rate (CBR), and duration of response (DOR).

Results: The CMAB009 plus irinotecan arm demonstrated significantly improved ORR (33.2% vs. 12.8%; \( P < 0.001 \)) and longer median PFS (169 days vs. 95 days; \( P < 0.001 \)) as compared to the irinotecan-only arm. Patients receiving irinotecan-only were permitted to switch to CMAB009 therapy on disease progression and were grouped as the sequential-CMAB009 arm. The primary endpoints were overall response rate (ORR) and median progression-free survival (PFS). The secondary endpoints were median overall survival (OS), disease control rate (DCR), clinical benefit rate (CBR), and duration of response (DOR).
Background

Colorectal cancer (CRC) is one of the most common malignant tumors, with an estimated 1.4 million new cases and nearly 700 thousand cancer deaths reported worldwide in the year 2012 [1]. The incidence and mortality rates of colorectal cancer rank fifth in China [2], and the incidence is still rising [3]. The prognosis of metastatic CRC (mCRC) is poor with a 5-year overall survival (OS) rate < 15% [4, 5]. Patients with unresectable mCRC receiving supportive care alone have been shown to have a poor prognosis, with a median OS of 5 months [6]. By contrast, the 5-year OS rate of patients with unresectable mCRC who received first-line chemotherapy with 5-fluorouracil (5-FU)/leucovorin (LV) plus oxaliplatin (FOLFOX) was 10% [7].

The FOLFOX regimen has become the standard first-line therapy for the treatment of unresectable mCRC [8–11]. Other recommended first-line chemotherapy regimens include capcitabine plus oxaliplatin (CapeOX), FOLFOX plus bevaczumab, CapeOX plus bevacizumab, and FOLFOX plus cetuximab (KRAS/NRAS wild type only) [12, 13]. However, after the failure with first-line therapy, which combination chemotherapy regimen would be the optimal second or third-line treatment is yet to be confirmed, as such strategic trials investigating these are urgently needed.

CMAB009, a recombinant, human/mouse chimeric monoclonal antibody (mAb) specifically targeting the human epidermal growth factor receptor (EGFR), competitively inhibits ligand-binding and interrelated downstream signaling. It has the same amino acid sequence as ERBITUX® (cetuximab), but slightly different abilities for glycosylation and other post-translational modifications (PTMs). CMAB009 is expressed by the Chinese hamster ovary (CHO) cells while cetuximab is expressed by the mouse cell line SP2/0 which also expresses the gene for α-1,3-galactosyltransferase [14]. In most patients who have developed a hypersensitivity reaction to cetuximab, IgE antibodies against the cetuximab were found to be already present in their serum prior to the start of the therapy [14]. These antibodies were found to be specific for galactose-α-1,3-galactose (Gal (α 1-3) Gal). Since CHO cells do not produce α-1,3-galactosyltransferase, they have a pattern of glycosylation that differs from that of SP2/0 [14–16], as such, CMAB009 expressed in CHO cells has a lower level of Gal (α 1-3) Gal-containing glycans [15]. This suggests that CMAB009 might have lower immunogenicity and reduced hypersensitivity reactions as compared to cetuximab.

In our previous retrospective study, we have shown that CMAB009 demonstrated good efficacy and acceptable tolerance in patients with chemotherapy-resistant advanced CRC [17]. In this study, we aimed to prospectively determine the clinical efficacy and safety of CMAB009 plus irinotecan as compared to that of irinotecan-only in KRAS wild-type mCRC patients who had treatment failure with first-line FOLFOX regimen.

Patients and methods

Patient selection

This prospective, open-label, randomized, phase III trial was conducted at 38 centers in China (Table 1). Patients were eligible if they had previous documented treatment failure (disease progression or discontinuation due to toxicity) with FOLFOX regimen for histologically confirmed mCRC and had wild-type KRAS mutation. Other inclusion criteria were: age between 18 and 70 years, an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1, a life expectancy of more than 3 months starting from the time of enrollment, no other malignant tumors, except for patients who had been cured for cervical carcinoma in situ, skin basal carcinoma, or squamous cell carcinomas. The exclusion criteria were: chemotherapy within 4 weeks prior to enrollment, abnormal serum hematologic function [hemoglobin (Hb)< 90 g/L; platelet count (PLT)< 100 × 10⁹/L; absolute neutrophil count (ANC)< 1.5 × 10⁹/L; or white blood cell count (WBC)< 4.0 × 10⁹/L], abnormal hepatorenal function (total bilirubin (TBIL), more than onefold higher than the upper limit of the normal range; blood urea nitrogen (BUN) and creatinine (Cr), more than 1.5-fold higher than the upper limit of the normal range;
or alanine aminotransferase (ALT) and aspartate aminotransferase (AST), more than fivefold higher than the upper limit of the normal range with hepatic metastases or more than 2.5-fold higher than the upper limit of the normal range without hepatic metastases], serious cardiac insufficiency, known history of brain metastases, and prior therapy with EGFR-targeting agents. Women who were pregnant or breastfeeding were also excluded.

The protocol of this study was approved by the ethics committee board at each center and all patients provided signed informed consent before participation.

Table 1  Eligible KRAS wild-type patients were identified at 38 hospitals in China

| Participating institutions                                                                 | Principle investigator in each institution | No. of patients |
|------------------------------------------------------------------------------------------|-------------------------------------------|-----------------|
| Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College    | Yuankai Shi                               | 18              |
| Fudan University Shanghai Cancer Center                                                  | Jin Li                                    | 42              |
| The Affiliated Hospital of Military Medical Sciences                                     | Jianming Xu                               | 38              |
| Shanghai General Hospital                                                                | Liwei Wang                                | 30              |
| Jilin Cancer Hospital                                                                    | Ying Cheng                                | 21              |
| Tumor Hospital of Hebei Province                                                         | Wei Liu                                   | 22              |
| The First Affiliated Hospital of Anhui Medical University                                | Guoping Sun                                | 23              |
| Fujian Provincial Cancer Hospital                                                        | Yigui Chen                                 | 24              |
| Chinese PLA General Hospital                                                             | Li Bai                                    | 20              |
| Zhejiang Cancer Hospital                                                                 | Yiping Zhang                               | 21              |
| Hunan Cancer Hospital                                                                    | Yi Luo                                    | 18              |
| Shandong Cancer Hospital                                                                  | Zhehai Wang                                | 18              |
| The First Hospital of China Medical University                                          | Yunpeng Liu                                | 18              |
| Tianjin People’s Hospital                                                                | Qiang Yao                                  | 15              |
| Sun Yat-sen University Cancer Center                                                     | Yuhong Li                                  | 14              |
| Chinese PLA Bayi Hospital                                                                | Shukui Qin                                 | 12              |
| The Guangxi Zhuang Autonomous Region Tumor Hospital                                      | Xiaohua Hu                                 | 12              |
| West China Hospital                                                                     | Feng Bi                                   | 11              |
| First Affiliated Hospital of Bengbu Medical College                                      | Rongsheng Zheng                           | 10              |
| Fuzhou PLA General Hospital                                                             | Xuenong Ouyang                            | 10              |
| Peking Union Medical College Hospital                                                    | Chunmei Bai                               | 10              |
| Tianjin Medical University Cancer Institute & Hospital                                   | Yi Ba                                     | 16              |
| Jiangsu Cancer Hospital                                                                  | Jiefeng Feng                              | 10              |
| General Hospital of Jinan Military Region                                                | Baochang Wang                             | 10              |
| Chongqing General Hospital                                                               | Min Fu                                    | 9               |
| The First Affiliated Hospital of The Third Military Medical University                   | Houjie Li                                 | 7               |
| Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology | Shiyong Yu                                | 7               |
| Ruijin Hospital, Shanghai Jiaotong University School of Medicine                        | Jun Zhang                                 | 6               |
| The Second Xiangya Hospital of Central South University                                 | Chunhong Hu                               | 6               |
| No. 3 People Hospital Affiliated to Shanghai Jiaotong University School of Medicine     | Bin Jiang                                 | 5               |
| Chongqing Cancer Hospital                                                                | Ying Xiang                                | 5               |
| Nanfang Hospital                                                                        | Rongwei Luo                               | 5               |
| The First Affiliated Hospital of Suzhou University                                       | Min Tao                                   | 4               |
| Affiliated Hospital of Nantong University                                                 | Guoxin Mao                                | 4               |
| Sichuan Provincial People’s Hospital                                                     | Honglin Hu                                | 3               |
| Gansu Provincial Cancer Hospital                                                        | Weihua Zhang                              | 3               |
| Xijing Hospital                                                                        | Wenchao Liu                               | 3               |
| Kunming General Hospital of Chengdu Military Command                                     | Hong Chen                                 | 2               |
Study design
Patients were randomly assigned in a 2:1 ratio to receive either CMAB009 (Shanghai Zhangjiang Biotech Co., Shanghai, China) plus irinotecan (Qilu Pharma, Jinan, Shandong, China) or irinotecan-only, respectively. Patients receiving irinotecan-only could switch to CMAB009 therapy (labeled as the sequential-CMAB009 arm) upon diagnosis of disease progression.

The primary endpoints were overall response rate (ORR) and median progression-free survival (PFS). ORR was defined as the proportion of patients with a confirmed complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumor (RECIST) version, 1.0. PFS was defined as the time from the date of entry into the trial to the date of first observed treatment failure (local and/or regional persistence/recurrence or distant metastasis) or death from any cause. The secondary endpoints were median OS (time from the date of entry into the trial to the date of death or the date the patient was last known to be alive), disease control rate [DCR, the duration of CR, PR, and stable disease (SD)], clinical benefit rate (CBR, defined as the sum of the number of patients who achieved CR, PR, and SD, and remained stable for a more than 24 weeks) and duration of response (DOR, time from the date of first evidence of CR or PR to the date of objective progression or the date of death due to any cause), and treatment safety.

Treatment
Patients assigned to the CMAB009 plus irinotecan arm received an initial dose of CMAB009 at 400 mg/m² intravenously over 2 h on day 1, and then 250 mg/m² over 1 h weekly. Irinotecan, at a dosage of 180 mg/m² intravenously, or 125–135 mg/m² intravenously for those with prior pelvic/abdominal irradiation, was given over 90 min and was administered every 2 weeks in both treatment arms; starting more than 1 h after the CMAB009 infusion completion for patients in the CMAB009 plus irinotecan arm. Each treatment cycle lasted 2 weeks. The dosage of CMAB009 for patients in the sequential-CMAB009 arm was similar to that of the CMAB009 plus irinotecan arm. The treatments were continued until disease progression, unacceptable toxicity, or the patient withdrew consent.

The National Cancer Institute Common Terminology Criteria for Adverse Event Criteria (NCI CTCAE) version 3.0 was used to assess adverse events. The definition and grading of hypersensitivity reactions were based on documented symptoms list in the criteria, the characteristics of grade 1 reaction were transient flushing or rash; drug fever < 38 °C; those of a grade 2 reaction were rash; flushing; urticaria; dyspnea; drug fever ≥ 38 °C; and those of a grade 3 reaction were symptomatic bronchospasm, with or without urticaria; parenteral medication(s) indicated; allergy-related edema/angioedema; hypotension. Anaphylaxis and death were considered as a grade 4 and 5 reaction, respectively. CMAB009 was discontinued upon the occurrence of grade 3/4 hypersensitivity, after which the dose of irinotecan was to be reduced to 125–135 mg/m² when grade 3/4 neutropenia, febrile neutropenia, thrombocytopenia, and leucopenia occurred. In the event of grade 4 nonhematologic toxicities (excluding diarrhea), both agents were discontinued.

Assay to detect mutant KRAS
The tissue specimens (surgery or biopsy from the primary or metastatic tumor) of mCRC patients were evaluated at the central laboratory of the Chinese National Human Genome Center in Shanghai, and only patients with available KRAS mutational status at codon 12, 13 were included. Formalin-fixed, paraffin-embedded tumor sections were deparaffinized and air dried, and DNA was extracted using standard Proteinase K digestion and a DNeasy minispin column (Qiagen, Valencia, CA, USA). Mutant KRAS was detected using a validated DNA sequencing method that identifies seven somatic mutations located in codons 12 and 13 (Gly12Asp, Gly12Ala, Gly12Val, Gly12Ser, Gly12Arg, Gly12Cys, and Gly13Asp) using allele-specific real-time polymerase chain reaction at the central laboratory of The Chinese National Human Genome Center, Shanghai, China [18, 19].

Response assessment
Measurable lesions were obtained at baseline (within the 4 weeks prior to the start of treatment) and evaluated every 6 weeks by computed tomography (CT) scans. Tumor response was assessed by local investigators based on the RECIST criteria version 1.0, until disease progression. After treatment completion, a follow-up assessment was conducted every 4 weeks, for up to 5 years after the last dose or until the patient succumbed or the last date of follow-up (July 23, 2015).

Immunogenicity assessment
Blood samples were taken at week 0 (before CMAB009 infusion) and at 6, 12, 18, and 30 weeks after the first infusion, to determine the presence of ADA, which was analyzed using a competitive inhibition assay by the Surface Plasmon Resonance (SPR) (Shanghai Zhangjiang Biotechnology, Shanghai, P. R. China) while presence of neutralizing ADAs (NAb) were analyzed by competitive enzyme-linked immunosorbent assay (ELISA) (Shanghai Zhangjiang Biotechnology, Shanghai, P. R. China).
Statistical analysis
At least 333 patients (CMAB009 plus irinotecan arm: 222 patients; irinotecan-only arm: 111 patients) were required to obtain a 90% power to detect an absolute difference in ORR. This in turn meant that after accounting for a typical study dropout rate of 10%, 495 patients (CMAB009 plus irinotecan: irinotecan-only, 330:165) were to be enrolled in the study to meet statistical requirements by satisfying the minimum number of patients outlined by the China Food and Drug Administration (CFDA, http://www.nmpa.gov.cn/WS04/CL2174/300629_9.html). An O’Brien and Fleming type α spending function was used to ensure an overall, two-sided, type I error rate of 5%. The ORR was compared between the treatment arms using a Cochrane–Mantel–Haenszel test stratified by ECOG PS score (0 vs. 1). DCR, CBR, and DOR were assessed according to RECIST criteria, version 1.0. PFS and OS were analyzed by the Kaplan–Meier method. Primary comparisons between the treatment arms were made using a two-sided log-rank test stratified by ECOG PS. Hazard ratios with 95% confidence intervals (CI) were calculated from stratified Cox regression models with gender, age, and ECOG PS score.

Results
Patient characteristics
Between May 31, 2009, and September 23, 2011, a total of 1077 patients were assessed for eligibility. There were 35 patients with insufficient or poor-quality DNA samples. The observed KRAS mutation (codons 12 and 13) rate was 32.3% (337/1042). After exclusion of non-eligible patients, 512 KRAS wild-type patients, 342 in the CMAB0009 plus irinotecan arm and 170 in the irinotecan-only arm, were enrolled from 38 sites in China (Fig. 1, Table 1). The study arms were well balanced for clinical characteristics (Table 2).

Treatment exposure
The median number of treatment cycles was 8 (1–80 cycles) for the CMAB009 plus irinotecan arm, 5 (1–27 cycles) for the irinotecan-only arm, and 4 (1–36 cycles) for the sequential-CMAB009 arm. The median irinotecan treatment duration was longer for the CMAB009 plus irinotecan arm (14.0 weeks; range 2.0 to 102.6 weeks) as compared to the irinotecan-only arm (10.0 weeks; range 2.0 to 53.2 weeks). In the CMAB009 plus irinotecan arm, the median CMAB009 treatment duration was 16.3 weeks (range 1.0 to 159.7 weeks). There were 115 patients who switched to CMAB009 treatment from the irinotecan-only therapy (sequential-CMAB009 arm) and the median treatment duration of CMAB009 was 7.4 weeks (range 1.0 to 72.0 weeks). The median dose intensity of irinotecan was higher in the irinotecan-only arm (97.6 mg/m²/week) than in the CMAB009 plus irinotecan arm (92.6 mg/m²/week). In the CMAB009 plus irinotecan arm, the median CMAB009 dose intensity was 263.3 mg/m²/week. For the sequential-CMAB009 arm, the median dose intensity was 286.4 mg/m²/week.

A dose modification of 35.0% (118/337) was recorded for irinotecan in the CMAB009 plus irinotecan arm and 20.1% (33/164) in the irinotecan-only arm. Dose modification for CMAB009 was 18.1% (61/337) in CMAB009 plus irinotecan arm and 12.2% (14/115) in the sequential-CMAB009 arm.

The safety analysis population consisted of patients who received at least one dose of the study drug and had at least one safety assessment after treatment administration (338 in the CMAB0009 plus irinotecan arm and 165 in the irinotecan-only arm). The efficacy analysis was performed in patients with at least one dose of the study drug and had complete baseline data (337 in the CMAB0009 plus irinotecan arm and 164 in the irinotecan-only arm) (Fig. 1).

Treatment efficacy
Primary endpoints
The tumor response was evaluated in 501 investigated patients. The ORR was 33.2% (112/337) and 12.8% (21/164) in the CMAB0009 plus irinotecan and irinotecan-only arms, respectively (P < 0.001, Table 3). For the sequential-CMAB009 arm, 13.9% (16/115) of the patients achieved PR and 49.6% (57/115) demonstrated SD. The median PFS was significantly longer in the CMAB0009 plus irinotecan arm than in the irinotecan-only arm (169 vs. 95 days; HR, 0.50; 95% CI 0.40 to 0.63; P < 0.001) (Fig. 2). In the sequential-CMAB009 arm, the median PFS was 84 days (95% CI 65–113 days).

Secondary endpoints
Median OS was 425 days in the CMAB0009 plus irinotecan arm and 401 days in the sequential-CMAB009 arm (HR, 1.02; 95% CI 0.82 to 1.28; P = 0.940) (Fig. 3). The DCR and CBR were higher for patients in the CMAB009 plus irinotecan arm as compared to the irinotecan-only arm (both P < 0.001, Table 3). In the sequential-CMAB009 arm, the DCR and CBR were 63.5% and 23.1%, respectively.

DOR in the CMAB009 plus irinotecan arm was almost twice of that in the irinotecan-only arm (210 vs. 109 days, HR, 0.39; 95% CI 0.22 to 0.66; P < 0.001; Fig. 4). For the sequential-CMAB009 arm, the DOR was 148 days (95% CI 59 to 230 days).

Treatment safety
Over the course of the study, 96.2% (484/503) of patients experienced at least one adverse event. There
were 55.3% (187/338) of patients in the CMAB009 plus irinotecan arm and 37.6% (62/165) of patients in the irinotecan-only arm who experienced at least one grade \( \geq 3 \) adverse event. Although the frequency and severity of some adverse events were greater in the CMAB009 plus irinotecan arm, however, CMAB009 plus irinotecan was generally well-tolerated. The most common adverse events (Table 4) consisted of diarrhea (39.6% vs. 35.8%), emesis (18.9% vs. 37.0%), leucopenia (50.0% vs. 39.4%), neutropenia (30.5% vs. 19.4%), and fatigue (22.2% vs. 16.4%) in CMAB009 plus irinotecan and irinotecan-only arms, respectively. Hypersensitivity reactions were experienced in 0.9% (4/453)
of patients in this study, three (one grade 1, one grade 2 and one grade 3) in the CMAB009 plus irinotecan arm and one (grade 2) in the sequential-CMAB009 arm (Table 4). As expected, the addition of CMAB009 to irinotecan significantly increased the risk of skin rash (66.9% vs. 5.5%, \( P < 0.001 \)) and paronychia (9.8% vs. 0.0%, \( P < 0.001 \)). Additionally, one patient in the sequential-CMAB009 arm developed grade 4 neutropenia but was determined unrelated to the CMAB009.

**Table 2 Baseline demographic and clinical characteristics of the 501 patients before the start of treatment**

| Characteristic | CMAB009 plus irinotecan \((n = 337)\) | Irinotecan-only \((n = 164)\) | Entire study cohort \((n = 501)\) | \(P\) |
|---------------|---------------------------------|-------------------------|-------------------------------|------|
| No. of patients | % | No. of patients | % | No. of patients | % |
| **Age, years** | | | | | 0.652 |
| Median | 55.0 | 55.0 | 55.0 | | |
| Standard deviation | 10.55 | 11.02 | 10.69 | | |
| < 65 | 287 | 85.2 | 141 | 86.0 | 428 | 85.4 |
| ≥ 65 | 50 | 14.8 | 23 | 14.0 | 73 | 14.6 |
| **Sex** | | | | 0.246 |
| Male | 195 | 57.9 | 104 | 63.4 | 299 | 59.7 |
| Female | 142 | 42.1 | 60 | 36.6 | 202 | 40.3 |
| **Ethnic minority** | | | | 0.121 |
| Han | 334 | 99.1 | 159 | 97.0 | 493 | 98.4 |
| Other | 3 | 0.9 | 5 | 3.0 | 8 | 1.6 |
| **ECOG performance status** | | | | 0.120 |
| 0 | 136 | 40.4 | 56 | 34.1 | 192 | 38.3 |
| 1 | 201 | 59.6 | 107 | 65.2 | 308 | 61.5 |
| 2 | 0 | 0 | 1 | 0.6 | 1 | 0.2 |
| **Previous therapy** | | | | 0.667 |
| Chemotherapy | 337 | 100 | 163 | 99.4 | 500 | 99.8 |
| Radiation therapy | 92 | 27.3 | 37 | 22.6 | 129 | 25.7 |
| **First-line therapy** | | | | 0.277 |
| Median duration, months | 6 | 7 | 7 | | |
| Range, months | 1–38 | 1–24 | 1–38 | | |
| **Reason off therapy** | | | | 0.552 |
| Disease progression | 301 | 66.8 | 144 | 63.7 | 445 | 65.8 |
| Adverse events | 41 | 9.1 | 25 | 11.1 | 66 | 9.7 |
| Other | 108 | 24.0 | 57 | 25.2 | 165 | 24.4 |
| **Site of metastasis** | | | | 0.873 |
| Lung | 142 | 42.1 | 73 | 44.5 | 215 | 42.9 |
| Peritoneum | 25 | 7.4 | 17 | 10.4 | 42 | 8.4 |
| Liver | 186 | 55.2 | 99 | 60.4 | 285 | 56.9 |
| Lymph node | 106 | 31.5 | 60 | 36.6 | 166 | 33.1 |
| Other | 105 | 31.2 | 50 | 30.5 | 155 | 30.9 |
| **No. of disease sites** | | | | 0.199 |
| 1 | 98 | 29.1 | 38 | 23.2 | 136 | 27.1 |
| ≥ 2 | 239 | 70.9 | 126 | 76.8 | 365 | 72.9 |

ECOG, Eastern Cooperative Oncology Group

* There was no significant difference in baseline patient characteristics between the 2 groups

**Immunogenicity**

A total of 1115 serum samples were obtained from 310 patients (249 patients from the CMAB009 plus irinotecan arm and 61 patients from the sequential-CMAB009 arm) and were analyzed for the presence of ADA, which was detected in only 3.6% (11/310) of patients. Excluding 4 patients with pre-existing ADA, the incidence of ADA in this study cohort was found to be 2.3% (7/310) (Table 5). All the ADA positive patients were in the CMAB009 plus irinotecan arm and none in the sequential-CMAB009 arm.
arm. Samples positive for binding antibodies in the confirmatory ADA assay were further evaluated for the presence of NAb to the CMAB009, of which 1.3% (4/310) patients were found to be positive (Table 5). No significant differences in clinical safety were found between ADA positive patients and ADA negative patients.

**Discussion**

This is the first prospective, open-label, randomized, phase III study comparing the clinical efficacy and safety of an anti-EGFR monoclonal antibody in KRAS wild-type mCRC patients with documented previous failure with FOLFOX regimen. In this study, we have found that patients treated with CMAB009 plus irinotecan demonstrated significantly better ORR and prolonged PFS as compared with those having irinotecan-only. In addition, the combination treatment with CMAB009 was generally well-tolerated and manageable. Therefore, this regimen could be considered as a new standard of treatment in the second-line setting for KRAS wild-type mCRC patients after failure with the FOLFOX regimen.

From the knowledge of the predictive value of KRAS mutation (codons 12 and 13) status for the efficacy of cetuximab, wild-type KRAS is required for evaluating cetuximab efficacy in mCRC patients [19–23]. **KRAS**

---

Table 3 Therapeutic efficacies of CMAB009 plus irinotecan treatment versus irinotecan-only treatment

| Treatment response | CMAB009 plus irinotecan (n = 337) | Irrinotecan-only (n = 164) | P* |
|--------------------|-----------------------------------|--------------------------|----|
|                     | No. of patients | %                  | No. of patients | %                  |
| CR                 | 4                  | 1.2                | 1              | 0.6                |
| PR                 | 108                | 32.0              | 20             | 12.2               |
| SD                 | 158                | 46.9              | 86             | 52.4               |
| PD                 | 47                 | 13.9              | 44             | 26.8               |
| Not evaluable      | 20                 | 5.9               | 13             | 7.9                |
| ORRa               | 112/337            | 33.2              | 21/164         | 12.8 < 0.001      |
| 95% CI of ORR      | 28.2–38.5          |                   | 8.1–8.9        |                   |
| DCRb               | 270/337            | 80.1              | 107/164        | 65.2 < 0.001      |
| 95% CI of DCR      | 75.5–84.2          |                   | 57.4–72.5      |                   |
| CBRc               | 101/337            | 30.0              | 24/164         | 14.6 < 0.001      |
| 95% CI of CBR      | 25.1–35.2          |                   | 9.6–21.0       |                   |

CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; response classified by Response Evaluation Criteria in Solid Tumors (RECIST, version 1.0); ORR, overall response rate; DCR, disease control rate; CBR, clinical benefit rate

*Cochran–Mantel–Haenszel test stratified by Eastern Cooperative Oncology Group performance status (0 vs. 1) at random assignment

a Overall response either CR or PR

b Overall response CR PR or SD

c Overall response CR PR or SD, ≥ 24 weeks

---

Fig. 2 Kaplan-Meier analysis comparing the progression-free survival of patients from the CMAB009 plus irinotecan arm to those in the irinotecan-only arm only. PFS, progression free survival; HR, hazard ratio; CI, confidence intervals
Fig. 3 Kaplan-Meier analysis comparing the overall survival of patients from the CMAB009 plus irinotecan arm to those in the sequential-CMAB009 arm. OS, overall survival; HR, hazard ratio; CI, confidence intervals

Fig. 4 Kaplan–Meier analysis for the duration of treatment response. Median DOR was significantly longer in patients who received CMAB009 plus irinotecan compared with those who received irinotecan-only. DOR, duration of response
mutations have been reported in 30% to 50% of CRC tumors and are also common in other tumor types [19]. In the present study, of the 1077 mCRC initially assessed in the KRAS analyses, of which the KRAS status in 35 patients could not be determined due to insufficient or poor-quality DNA samples, only 512 patients were found to have KRAS wild-type mCRC, demonstrating an observed KRAS mutations incidence of 32.3%. This was within the expected range of previous studies which reported mutation rates of approximately 36% [24–26].

Treatment with CMAB009 plus irinotecan, as compared to irinotecan-only, demonstrated significantly improved ORR, reduced the risk of disease progression by nearly 50% (PD, 13.9% vs. 26.8%, respectively), improved clinical efficacy (DOR, 210 days vs. 109 days; DCR, 80.1% vs. 65.2%; CBR, 30.0% vs. 14.6%, respectively), and had an acceptable safety profile. Further, the findings of this study showed that when CMAB009 was used as a third-line treatment in the sequential-CMAB009 arm, 13.9% (16/115) of the patients achieved PR with a PFS of 84 days, and 49.6% (57/115) of the patients achieved SD, comparable with the results of the CO.17 Trial [27] from the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), in which cetuximab was found to significantly improve PR (8%), SD (31.4%), and quality of life compared to the best supportive care in CRC patients in whom other treatments had failed. Several studies have reported the combination of irinotecan with other drugs, such as modified XELIRI (mXELIRI, capecitabine plus irinotecan) regimen and FOLFIRI (leucovorin, fluorouracil, and irinotecan), with or without bevacizumab regimens. The median OS for mXELIRI with or without bevacizumab was found to be non-inferior (16.8 months vs. 15.4 months) to FOLFIRI with or without bevacizumab regimens for mCRC [28]. A small-scale retrospective study reported that a re-challenge strategy with cetuximab and irinotecan may be active in patients with RAS.

| Parameters                  | CMAB009 plus irinotecan (n = 338) | Irinotecan-only (n = 165) |
|-----------------------------|----------------------------------|---------------------------|
|                            | All grades grade | Grade 3/4 | All grades grade | Grade 3/4 |
|                            | n   | %    | n   | %    | n   | %    | n   | %    |
| Any drug-related AEa        | 334 | 98.8 | 187 | 55.3 | 150 | 90.9 | 62  | 37.6 |
| Diarrhea                    | 134 | 39.6 | 35  | 10.4 | 59  | 35.8 | 12  | 7.3  |
| Emesis                      | 64  | 18.9 | 14  | 4.1  | 61  | 37.0 | 13  | 7.9  |
| Leucopenia                  | 169 | 50.0 | 54  | 16.0 | 65  | 39.4 | 15  | 9.1  |
| Neutropenia                 | 103 | 30.5 | 54  | 16.0 | 32  | 19.4 | 14  | 8.5  |
| Fatigue                     | 75  | 22.2 | 9   | 2.7  | 27  | 16.4 | 6   | 3.6  |
| Special AEb                 | 226 | 66.9 | 22  | 6.5  | 9   | 5.5  | 1   | 0.6  |
| Rash                        | 33  | 9.8  | 4   | 1.2  | 0   | 0    | 0   | 0.0  |
| Paronychia                  | 2   | 0.6  | 1   | 0.3  | 1   | 0.6  | 0   | 0.0  |
| Hypersensitivity reaction   | 3   | 0.9  | 1   | 0.3  | 1c  | 0.9c | 0c  | 0c   |

AE, adverse events
a Includes cases having special adverse events
b Special adverse events were categorized based on events that occurred in previous study and were reported for CMAB009 related-toxicities
c Sequential-CMAB009 arm (n = 115)

| Parameters                  | CMAB009 plus irinotecan (n = 338) | Irinotecan-only (n = 165) |
|-----------------------------|----------------------------------|---------------------------|
|                            | All grades grade | Grade 3/4 | All grades grade | Grade 3/4 |
|                            | n   | %    | n   | %    | n   | %    | n   | %    |
| Any drug-related AEa        | 334 | 98.8 | 187 | 55.3 | 150 | 90.9 | 62  | 37.6 |
| Diarrhea                    | 134 | 39.6 | 35  | 10.4 | 59  | 35.8 | 12  | 7.3  |
| Emesis                      | 64  | 18.9 | 14  | 4.1  | 61  | 37.0 | 13  | 7.9  |
| Leucopenia                  | 169 | 50.0 | 54  | 16.0 | 65  | 39.4 | 15  | 9.1  |
| Neutropenia                 | 103 | 30.5 | 54  | 16.0 | 32  | 19.4 | 14  | 8.5  |
| Fatigue                     | 75  | 22.2 | 9   | 2.7  | 27  | 16.4 | 6   | 3.6  |
| Special AEb                 | 226 | 66.9 | 22  | 6.5  | 9   | 5.5  | 1   | 0.6  |
| Rash                        | 33  | 9.8  | 4   | 1.2  | 0   | 0    | 0   | 0.0  |
| Paronychia                  | 2   | 0.6  | 1   | 0.3  | 1   | 0.6  | 0   | 0.0  |
| Hypersensitivity reaction   | 3   | 0.9  | 1   | 0.3  | 1c  | 0.9c | 0c  | 0c   |

AE, adverse events
a Includes cases having special adverse events
b Special adverse events were categorized based on events that occurred in previous study and were reported for CMAB009 related-toxicities
c Sequential-CMAB009 arm (n = 115)
and \textit{BRAF} wild-type mCRC with acquired resistance to first-line irinotecan- and cetuximab-based therapy [29]. These results showed that CMAB009/cetuximab plus irinotecan might have good clinical efficacy in \textit{KRAS} wild-type mCRC patients.

This study was also designed to explore whether CMAB009 plus irinotecan therapy would prolong OS. Our results showed that the median OS was similar between the CMAB009 plus irinotecan and sequential-CMAB009 arms (425 days vs. 401 days, \(P = 0.940\)), which we presume was possibly influenced by the sequential CMAB009 treatment in the patients after irinotecan failure, and thereby indicated that either CMAB009 plus irinotecan or sequential-CMAB009 may be considered as an effective treatment choice.

The safety profile of CMAB009 plus irinotecan in our study was comparable with that of other anti-EGFR monoclonal antibodies [27, 30–32]. Skin rash is associated with all EGFR inhibitors and is the most frequently associated with cetuximab/CMAB009. This adverse event seems to be closely linked to the biologic activity of cetuximab/CMAB009 as EGFR is expressed on the epidermal keratinocytes and hair follicles, and is thought to play a role in maintaining the skin integrity and follicular homeostasis [33]. Therefore blocking these effects may be responsible for the observed rashes. As such, in the present study, the most noticeable adverse event related with CMAB009 was skin rash (66.9%), which was similar to the cetuximab-related acneiform rash reported in 76.3% of patients in the EPIC study [20]. Notably, the CMAB009 plus irinotecan arm did not significantly increase gastrointestinal toxicity as compared with the irinotecan-only arm.

Humans have baseline levels of antibodies against certain non-human glycans, including N-glycolylneuraminic acid (NGNA) and Gal (\(\alpha\) 1-3) Gal, and severe hypersensitivity reactions occurring during the initial infusion of cetuximab are mediated by preexisting IgE antibodies against cetuximab [14, 34]. A high prevalence of severe hypersensitivity reactions of approximately 2% was reported in patients who had been injected with cetuximab because cetuximab is attached to N-linked oligosaccharide containing the Gal (\(\alpha\) 1-3) Gal motif at the Fab region [16]. This non-human glycan may induce immunogenicity [35]. However, CMAB009 expressed in CHO and has a different glycosylation pattern not containing the NGNA or Gal (\(\alpha\) 1-3) Gal motif at the Fab region [34, 36]. Therefore, CMAB009 has lower immunogenicity than cetuximab and the presence of ADA was found to be low at 3.6% (11/310). Only 0.9% (4/453) of patients experienced hypersensitivity reactions in our study, three in the CMAB009 plus irinotecan arm and one in the sequential-CMAB009 arm (Table 4).

Our study had several limitations worth noting. First, this study did not analyze other biomarkers such as NRAS. It was recently reported that NRAS was mutated in 6% of mCRC and were associated with a shorter OS compared to wild-type patients [31]. One meta-analysis showed that non-functional mutation or loss of NRAS, \textit{BRAF}, \textit{PIK3CA}, and \textit{PTEN} predicted poor efficacy of cetuximab [31, 32]. Therefore, to demonstrate the predictive value of \textit{RAS} and \textit{BRAF}, we propose a prospective phase III study to explore the clinical efficacy and safety of CMAB009 plus FORFIRI as first-line chemotherapy in \textit{RAS}/\textit{BRAF} wild-type patients with mCRC in China. Second, there were some patients failing to provide serum samples and some samples could not be analyzed due to hemolysis. This is because the release of cellular material into the serum or plasma would have introduced additional confounding factors in the downstream analysis of such samples and were therefore excluded from the immunogenicity analysis. Third, the quality of life of the patients was not assessed.

\textbf{Conclusions}

Treatment with CMAB009 plus irinotecan, compared to irinotecan-only, demonstrated superior clinical efficiency and was well tolerated as a second-line of treatment in \textit{KRAS} wild-type mCRC patients with documented previous failure with the FOLFOX regimen. Therefore, this regimen could be considered as an optimal second-line treatment of choice for such patients. Further, for those whose disease progressed after being treated with irinotecan-only, as a second-line of treatment, switching to CMAB009 can be considered as an effective third-line of treatment.

\textbf{Abbreviations}

\begin{itemize}
  \item ADA: anti-drug antibodies
  \item CBR: clinical benefit rate
  \item CRC: colorectal cancer
  \item CHO cells: Chinese hamster ovary cells
  \item CapeOX: capecitabine plus oxaliplatin
  \item DCR: disease control rate
  \item DOR: duration of response
  \item EGFR: epidermal growth factor receptor
  \item FOLFOX: 5-fluorouracil (5-FU)/leucovorin
  \item FOLFIRI: 5-fluorouracil (5-FU)/leucovorin/irinotecan
  \item FORFIRI: 5-fluorouracil/leucovorin/irinotecan
  \item NRAS: nucleotide binding domain-containing protein
  \item mCRC: metastatic colorectal cancer
  \item OS: overall survival
  \item PFS: progression-free survival
  \item RAS: retinoblastoma-associated protein
  \item VAF: variant allele frequency
\end{itemize}

\textbf{Acknowledgements}

We thank the patients, their families, and all investigators who participated in the study. We thank Doctor Wei Zhachui and Tigermed Bio-pharmaceutical Technology Co., Ltd for data analysis and statistics. We also thank the Chinese National Human Genome Center at Shanghai for \textit{KRAS} mutation detection. We thank Doctor Shiyu Jiang for editorial assistance in preparing this manuscript.

\textbf{Authors’ contributions}

YKS is the principal investigator of this study. He designed the study, YS conceptualized the study. All authors contributed in executing the clinical trial, collection and analysis of the data, and writing of the manuscript. All authors agreed to be responsible for all aspects of the study. All authors read and approved the final manuscript.
Funding
Shanghai Zhangjiang Biotechnology Co., Ltd. initiated and support this study. This work was also supported by the Chinese National Major Project for New Drug Innovation (2012ZX0910103, 2015ZX09101002-001-001, and 2008ZX09512).

Availability of data and materials
The datasets obtained and analyzed during the present study are available from the corresponding author on reasonable request.

Ethical approval and consent to participate
This study was approved by the ethical review committee of each participating hospital in China. It was conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonization of Good Clinical Practice. All participating patients provided written informed consent.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Medical Oncology, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P. R. China. 2 Fudan University Shanghai Cancer Center, Shanghai 200032, P. R. China. 3 The Affiliated Hospital of Military Medical Sciences, Beijing 100071, P. R. China. 4 Shanghai General Hospital, Shanghai 200080, P. R. China. 5 Jilin Cancer Hospital, Changchun 130012, P. R. China. 6 Tumor Hospital of Hebei Province, Shijiazhuang 050011, Hebei, P. R. China. 7 The First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui, P. R. China. 8 Fujian Provincial Cancer Hospital, Fuzhou 350014, Fujian, P. R. China. 9 Chinese People's Liberation Army General Hospital, Beijing 100853, P. R. China. 10 Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang, P. R. China. 11 Hunan Cancer Hospital, Changsha 410013, Hunan, P. R. China. 12 Shandong Cancer Hospital, Jinan 250117, Shandong, P. R. China. 13 The First Hospital of China Medical University, Shenyang 110001, Liaoning, P. R. China. 14 Tianjin People’s Hospital, Tianjin 300012, P. R. China. 15 Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou 510060, Guangdong, P. R. China. 16 Chinese People's Liberation Army Bayi Hospital, Nanjing 210002, Jiangsu, P. R. China. 17 The Guangxi Zhuang Autonomous Region Tumor Hospital, Nanning 530021, Guangxi, P. R. China. 18 West China Hospital, Chengdu 610041, Sichuan, P. R. China. 19 First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, Anhui, P. R. China. 20 Fuzhou People’s Liberation Army General Hospital, Fuzhou 350025, Fujian, P. R. China.

Received: 24 July 2018 Accepted: 10 May 2019 Published online: 24 May 2019

References
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
2. Zheng R, Zeng H, Zhang S, Chen W. Estimates of cancer incidence and mortality in China. 2013. Chin J Cancer. 2017;36(1):66. https://doi.org/10.1186/s12096-017-1234-3.
3. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.
4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. https://doi.org/10.3322/caac.21387.
5. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018. https://doi.org/10.3322/caac.21492.
6. Lucas AS, O'Neil BH, Goldberg RM. A decade of advances in cytotoxic chemotherapy for metastatic colorectal cancer. Clin Colorectal Cancer. 2011;10(4):238–44. https://doi.org/10.1016/j.clcc.2011.06.012.
7. Gustavsson B, Carlsson G, Machover D, Petrelli N, Roth A, Schmoll HJ, et al. A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clin Colorectal Cancer. 2013;14(1):1–10. https://doi.org/10.1016/j.clcc.2014.11.002.
8. Thirion P, Michiels S, Pignon J, Buyse M, Braun A, Carlson R, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol. 2004;22(18):3766–75. https://doi.org/10.1200/JCO.2004.3.104.
9. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil–leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18(1):136.
10. Bokemeyer C, Bondarenko I, Hartmann M, De Braud F, Schuch G, Zabel B, et al. Efficacy according to biomarker status of cetuximab plus FOLFIRI as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol. 2011;22(7):1535–46.
11. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22(1):23–30.
12. Mitsudomi T, Yabaci Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FBJS. 2010;27(2):301–8. https://doi.org/10.1174/1539-4428.2010.04748x.
13. Lee SY, Oh SC. Advances in targeted therapy in treatment of unresectable metastatic colorectal cancer. Biomed Res Int. 2016;2016:7590245. https://doi.org/10.1155/2016/7590245.
14. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose. N Engl J Med. 2008;358(11):1109–17.
15. Wang C, Guo H. Characterization of N-glycosylation in an anti-EGFR monoclonal antibody produced by different expression systems. Sheng Wu Gong Cheng Xue Bao. 2017;33(8):1018–27. https://doi.org/10.13435/j.cb.170874.
16. van Buuren JJJ, Rispens T, Verpoelgen S, van der Palen-Merkus T, Stapel S, Workman LJ, et al. Anti-galactose-α1,3-galactose IgE from allergic patients does not bind α-galactosylated glycans on intact therapeutic antibody Fc domains. Nat Biotechnol. 2011;29(7):574.
17. He X, Shi Y, Qin Y, Yang S, Sun Y. Phase I study of anti-EGFR monoclonal antibody (CMAB009) in patients with advanced cancer. Zhonghua yi xue za zhi. 2011;91(33):2335–3.
18. Whitcombe D, Theaker J, Guy SP, Brown T, Little S. Detection of PCR products using self-probing amplicons and fluorescence. Nat Biotechnol. 1999;17(8):804.
19. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with untreated metastatic colorectal cancer: an updated meta-analysis. J Clin Oncol. 2008;26(10):1626–34. https://doi.org/10.1200/JCO.2007.13.1193.
20. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakry YA, Lutz MP, et al. EPIC. phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(14):2311–9. https://doi.org/10.1200/JCO.2007.13.1193.
21. Lieve A, Bachet JB, Le Corre D, Boige V, Landi B, Emilie JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66(8):3992–5. https://doi.org/10.1158/0008-5472.CAN-06-0191.
22. Gill S, Goldberg RM. Targeted therapies: cetuximab, chemotherapy and KRAS status in mCRC. Nat Rev Clin Oncol. 2009;6(7):379.
23. Van Cutsem E, Kohne C-H, Läng I, Polprecht G, Nowacki MP, Cascini S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29(15):2011–9.
24. McLellan E, Owen R, Stepniowska K, Sheffield J, Lemoine N. High frequency of K-ras mutations in sporadic colorectal adenomas. Gut. 1993;34(3):392–6.
25. Arber N, Shapira I, Ratan J, Stern B, Hibshoosh H, Moshkowitz M, et al. Activation of cK-ras mutations in human gastrointestinal tumors. Gastroenterology. 2000;118(6):1045–50.
26. Van Cutsem E, Köhne C-H, Hitre E, Zaluski J, Chang Chien C-R, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408–17.
27. Jonker DJ, O’callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au H-J, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357(20):2040–8.
28. Xu R-H, Muro K, Morita S, Iwasa S, Han SW, Wang W, et al. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol. 2018;19(5):660–71.
29. Cremolini C, Rossini D, Dell’Aquila E, Lonardi S, Conca E, Del Re M, et al. Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial. JAMA Oncol. 2019;5(3):343–50.
30. Schirripa M, Cremolini C, Loupakis F, Morvillo M, Bergamo F, Zoratto F, et al. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. Int J Cancer. 2015;136(1):83–90.
31. Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis. Acta Oncol. 2014;53(7):852–64.
32. Cunningham D, Humbert Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337–45.
33. Lenz HJ. Cetuximab in the management of colorectal cancer. Biol Targets Ther. 2007;1(2):77.
34. Zhang P, Woen S, Wang T, Liau B, Zhao S, Chen C, et al. Challenges of glycosylation analysis and control: an integrated approach to producing optimal and consistent therapeutic drugs. Drug Disc Today. 2016;21(5):740–65.
35. Kawasaki N, Itoh S, Hashii N, Takakura D, Qin Y, Huang X, et al. The significance of glycosylation analysis in development of biopharmaceuticals. Biol Pharm Bull. 2009;32(5):796–800.
36. Batra J, Rathore AS. Glycosylation of monoclonal antibody products: current status and future prospects. Biotechnol Prog. 2016;32(5):1091–102.